SenesTech Strengthens Direct-to-Consumer Commercial Strategy by Directly Managing Amazon Sales of Evolveâ"¢ Rat and Evolveâ"¢ Mouse [Accessibility Statement] Skip NavigationTransition from Third-Party to Internal Management Expected to Increase Revenue and Enhance Margin on E-Commerce Channel Moving Forward While Building on Early SuccessPHOENIX, Feb. 10, 2026 /PRNewswire/ -- SenesTech, Inc. (Nasdaq: SNES) today announced that it will begin directly managing sales of its Evolveâ"¢ Rat and Evolveâ"¢ Mouse pr ...

Core Viewpoint - SenesTech, Inc. is initiating a search for a new CEO as current CEO Joel Fruendt plans to retire, with Dr. Jamie Bechtel appointed as Interim Executive Chair to support the transition [1][3]. Group 1: Leadership Transition - Joel Fruendt, who joined SenesTech in 2022, has informed the Board of his intent to retire, and he will remain in his position until a successor is found or until June 30, 2026 [1][2]. - The Board will engage an executive search firm to assist in identifying a qualified successor for the CEO role [4]. Group 2: Interim Leadership - Dr. Jamie Bechtel has been appointed as Interim Executive Chair to support the management team during the transition, focusing on strategic alignment and communication [3][4]. - The current COO Michael Edell and CFO Tom Chesterman will continue to lead day-to-day operations during this transitional period [4]. Group 3: Company Mission and Products - SenesTech is dedicated to humane pest management through fertility control, with its flagship product Evolve® aimed at enhancing pest management effectiveness while reducing reliance on traditional poisons [5]. - The company's mission is to create healthier environments, cleaner cities, and more efficient businesses through sustainable solutions [5].

Core Insights - SenesTech, Inc. has appointed Sarah Mann and the Belize Raptor Center as the new international distributor for Evolve® Rat Birth Control, aimed at managing rodent populations in Belize [1][2] - The introduction of Evolve Rat in Belize is a response to the ecological threats posed by unregulated rodenticides, which have led to secondary wildlife poisonings [2][3] - A grassroots education campaign has been launched to inform the public about the dangers of traditional rodenticides and promote fertility control as a humane alternative [3][4] Company Overview - SenesTech is focused on creating healthier environments through humane management of animal pest populations via fertility control, with Evolve Rat Birth Control being a key product [6] - The company aims to enhance pest management programs while reducing reliance on traditional poisons, contributing to cleaner cities and healthier communities [6] Market Context - Belize's biodiversity is under threat from the increased use of rodenticides, prompting the need for sustainable solutions like Evolve Rat Birth Control [2][4] - The partnership with local conservationists reflects a growing trend of adopting fertility control methods in integrated pest management programs globally [4]

Core Insights - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] Group 1 - The article suggests that users may face blocks if they have ad-blockers enabled, indicating a need to disable them for proper access [1]

Financial Data and Key Metrics Changes - The company reported record quarterly revenues of $690,000, representing a 43% increase year-over-year and a 10% increase sequentially [17] - Gross margins remained strong at 63%, with gross profit increasing to $433,000 from $315,000 [19] - Adjusted EBITDA loss was the best in the company's history at $1.2 million, compared to $1.4 million in the previous year [7][20] Business Line Data and Key Metrics Changes - Evolved revenue increased by 77% and accounted for 85% of total sales in Q3 [17] - E-commerce sales represented 54% of total revenue, up 55% year-over-year [17][18] - Municipal revenue grew 139% year-over-year, driven by deployments in major cities [11][18] Market Data and Key Metrics Changes - Retail sales surged by 254% year-over-year, primarily due to expanded adoption through Ace Hardware and Bradley Caldwell [11][18] - Pest management professionals (PMP) accounted for 19% of sales, up 29% year-over-year and 72% sequentially [18][14] Company Strategy and Development Direction - The company aims to achieve profitability through high-margin revenue growth and efficient expense management [6][8] - Expansion into brick-and-mortar retail is being pursued, with discussions ongoing for test deployments in Lowe's stores [24] - The company is focusing on increasing production capacity and operational efficiency to meet future demand [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the cash position of over $10 million, indicating a potential path to profitability without further equity offerings [8][20] - The adoption of the evolved rodent birth control solution is seen as a game-changer, with a large addressable market and regulatory tailwinds [22] Other Important Information - The company faced legal challenges from Levitech regarding alleged IP infringement, which management described as baseless [34] - Recent field trials in Somerville and Cambridge are progressing well, with expectations for future orders based on positive results [35] Q&A Session Summary Question: Will the company's products be available in Lowe's brick-and-mortar stores? - The company is in discussions for a test deployment in about 100 stores, with expectations for late Q2 [24] Question: What growth is expected from PMP-driven sales? - PMP is a key growth channel, with significant growth anticipated as awareness of birth control in pest management increases [25] Question: How much of the revenue was from e-commerce? - E-commerce accounted for 54% of quarterly revenue, consistent with previous quarters [26] Question: Is there a plan to adjust pricing for Evolve? - The company is comfortable with the current pricing strategy but may consider discounts for large orders in the future [27] Question: What is the progress in international markets? - The company received approval for distribution in New Zealand and is working on obtaining approvals in other countries [29][30] Question: Can you provide details on the legal expenses? - The company is facing a lawsuit from Levitech, which management believes is an attempt to hinder their business [34] Question: What revenue is expected from recent field trials? - It is too early to project revenues, but positive results from trials are expected to lead to future orders [35]

Revenue and Sales Performance - Revenues for Q3 2025 were $690,000, a 43% increase from $482,000 in Q3 2024, driven primarily by Evolve product sales [103]. - Evolve product sales accounted for approximately 85% of Q3 2025 revenues, up from 69% in Q3 2024, indicating strong market adoption [105]. - For the nine months ended September 30, 2025, revenues were $1.8 million, a 33% increase from $1.356 million in the same period of 2024 [103]. - Evolve product sales represented approximately 83% of revenues for the nine months ended September 30, 2025, compared to 63% in the same period of 2024 [106]. Profitability and Loss - Gross profit for Q3 2025 was $433,000, representing a margin of 62.8%, compared to $315,000 and a margin of 65.4% in Q3 2024 [110]. - The net loss for Q3 2025 was $1.298 million, a 14% improvement compared to a net loss of $1.513 million in Q3 2024 [103]. - The company incurred a net loss of $1.3 million for Q3 2025, continuing to rely on equity sales for funding operations [118]. Operating Expenses - Operating expenses for Q3 2025 totaled $1.78 million, a 4% decrease from $1.86 million in Q3 2024 [103]. - Research and development expenses for Q3 2025 were $400,000, a decrease of $51,000 (11.3%) from $451,000 in Q3 2024, primarily due to cost containment efforts [112]. - For the nine months ended September 30, 2025, research and development expenses totaled $1.2 million, down $43,000 (3.3%) from $1.3 million in the same period of 2024, driven by overall reductions in spending [113]. - Selling, general and administrative expenses for Q3 2025 were $1.4 million, consistent with Q3 2024, with increases in legal fees and franchise fees offsetting cost containment efforts [114]. - For the nine months ended September 30, 2025, selling, general and administrative expenses increased to $4.5 million, up $131,000 (3.0%) from $4.4 million in the same period of 2024, primarily due to higher legal fees [115]. Cash Flow and Financing - Cash flows from financing activities for the nine months ended September 30, 2025, included net proceeds of $10.5 million from warrant exercises and $2.7 million from common stock issuance [131]. - Cash used in investing activities for the nine months ended September 30, 2025, totaled $3.0 million for held-to-maturity investments and $125,000 for property and equipment purchases [129]. - The Warrant Inducement Transaction resulted in the issuance of 1,458,872 shares of common stock at an exercise price of $4.15 per share, generating gross proceeds of $6.3 million [132]. - The new warrants issued relate to 2,188,308 shares of common stock with an exercise price of $5.25 per share, expiring 15 months after the effective date of the resale registration statement [132]. - Placement agent warrants were issued to purchase up to 72,944 shares of common stock at an exercise price of $5.4219 per share [132]. Financial Position and Future Outlook - As of September 30, 2025, the company reported an accumulated deficit of $140.7 million and cash and cash equivalents totaling $10.2 million [119]. - The company expects cash and cash equivalents, along with anticipated revenue, to be sufficient to fund operations for the next 12 months [120]. - The company believes existing cash and investments will be sufficient for the foreseeable future [133]. - The company’s ability to continue as a going concern will depend on generating sufficient revenues, reducing operating costs, or obtaining additional funding if break-even or profitability is not achieved [133]. Market Opportunity - The market opportunity for non-poison rodent control is significant and growing, driven by regulatory restrictions on traditional rodenticides [102]. Accounting Policies - There have been no material changes to critical accounting policies and estimates as disclosed in the Annual Report for the year ended December 31, 2024 [134]. - No quantitative or qualitative disclosures about market risk were applicable [135].

Revenue Growth - Revenues increased by 43% to $690,000 in Q3 2025, a record for the company, compared to $482,000 in Q3 2024[4] - Evolve® Rodent Birth Control product sales grew 77% year-over-year, now representing 85% of total revenue[4] - Municipal revenue grew 139% year-over-year due to expanded deployments in cities like New York and Chicago[4] - Retail revenue increased by 254% year-over-year, driven by expanded adoption by Ace Hardware and follow-on orders from Bradley Caldwell[4] - E-commerce revenue rose 55% year-over-year, with significant growth in Amazon sales and other platforms[4] - Pest management professionals contributed to a 29% year-over-year revenue increase, representing nearly 20% of total revenue[5] Financial Performance - Adjusted EBITDA loss improved to $1.2 million in Q3 2025, compared to $1.4 million in the same quarter of the prior year[4] - Net loss for Q3 2025 was $1.3 million, an improvement from $1.5 million in Q3 2024[4] - The gross profit margin was 62.8%, in line with expectations[4] Cash Position - Cash and short-term investments totaled $10.2 million, providing a solid operating runway for the foreseeable future[4]

Core Insights - SenesTech, Inc. reported a 43% increase in revenues to $690,000 for Q3 2025, marking a record for the company, with Evolve® Rodent Birth Control product sales growing 77% year-over-year, now accounting for 85% of total revenue [7][4][1] Financial Highlights - Revenues increased to $690,000 from $482,000 in Q3 2024, representing a 43% growth [7] - Gross profit margin was reported at 62.8% [7] - Net loss for Q3 2025 was $1.3 million, an improvement from a loss of $1.5 million in Q3 2024 [7] - Adjusted EBITDA loss improved to $1.2 million, compared to $1.4 million in the same quarter of the prior year [7] - Cash and short-term investments totaled $10.2 million, providing a solid operating runway [7] Operational and Strategic Highlights - Evolve Rat and Evolve Mouse products, launched in 2024, grew 77% year-over-year and are the largest revenue drivers, representing 85% of total revenue [7] - E-commerce revenue increased by 55% year-over-year, with significant growth in Amazon sales [7] - Municipal revenue grew 139% year-over-year, driven by expanded deployments in cities like New York and Chicago [7] - Retail revenue surged 254% year-over-year, largely due to increased adoption by Ace Hardware and follow-on orders from Bradley Caldwell [7] - Revenue from pest management professionals increased by 29% year-over-year, contributing nearly 20% of overall revenue for Q3 2025 [7]

Core Insights - SenesTech, Inc. has launched its Evolve® Rat Birth Control® product on Lowes.com, marking a significant milestone in consumer accessibility and retail distribution [1][4][5] - Evolve Rat is the first soft bait targeting rat reproduction, providing a humane and sustainable solution to manage rat populations without poisons [2][4] - The partnership with Lowes, which has over 1,700 stores and $11 billion in online sales, is expected to enhance brand visibility and accelerate adoption among consumers [3][4] Company Overview - SenesTech focuses on humane pest management through fertility control, aiming to create healthier environments by reducing reliance on traditional poisons [5] - The company’s mission includes creating cleaner cities and healthier communities with effective and sustainable products [5] Market Opportunity - The launch on Lowes.com is seen as a strategic move to expand Evolve Rat's retail footprint, potentially leading to stronger revenue streams and increased market presence [4][8] - The product addresses a critical issue in pest management by targeting the root cause of population growth rather than merely increasing death rates [4][7]

Core Insights - SenesTech, Inc. will report its third quarter 2025 financial results on November 10, 2025, after market close, followed by a conference call at 5:00 p.m. Eastern time to discuss the results [1][2] Company Overview - SenesTech is focused on humane pest management through fertility control, having developed ContraPest®, the only U.S. EPA-registered contraceptive for both male and female rats, along with Evolve Rat and Evolve Mouse, which are EPA-designated minimum risk contraceptives for rodents [3] Conference Call Details - The conference call on November 10, 2025, will be accessible via a live webcast, with a replay available for 90 days on the company's Investor Relations website [2]